五一假期，本是人们外出游玩、放松身心的好时机。然而，时值春末夏初，气候多变，容易诱发呼吸道 疾病，其他症状好了，咳嗽却仍然持续不断，让美好的旅程大打折扣。面对恼人的咳嗽，很多人往往陷 入止咳误区。下面为容易出现的几个误区。 误区一：咳嗽不用治，过几天就好了 特别提醒，对于儿童、老人等特殊人群，用药更需谨慎。如果咳嗽持续不缓解，或伴有发热、胸痛等症 状，应及时就医。 误区三：咳嗽要用镇咳药，起效快 很多人一出现咳嗽症状，就立刻服用镇咳药，认为这样就能快速止咳。然而，这种做法并不科学。对于 有痰的咳嗽，如果盲目使用镇咳药，会导致痰液无法排出，反而加重病情。因此，对于有痰咳嗽，一般 不建议使用镇咳药。 五一出游，科学止咳这样做 那么，五一出游时遇到咳嗽不止时该怎么办呢？首先，对于不同原因导致的咳嗽，应区分病因用药。 对于因过敏引起的咳嗽，应先查明过敏原，远离过敏原，必要时可以使用抗过敏药物。因呼吸道感染引 起的咳嗽，可根据病原体使用相对应的抗病毒和止咳药物。比如中成药连花清咳片，既能快速止咳，又 能化痰清咳，对于上呼吸道感染、气管-支气管炎、肺炎、慢阻肺等疾病引发的咳嗽、咳痰治疗，具有 止咳、化痰、清肺等多重优势。 ...

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].